6.3. clinical n3 disease (cn3). 6.3.1. diagnostic evaluation patients clinical n3 disease defined presence fixed inguinal mass (i.e., skin underlying structures) pelvic lymphadenopathy based upon imaging undergo complete staging evaluation including cross sectional imaging (i.e., pet/ct ct, see section 5.2.3), already performed . biopsy inguinal mass setting patient known diagnosis penile cancer required performed previously undiagnosed patient, needed, establish diagnosis facilitate accurate staging. 6.3.2. management strategy neoadjuvant chemotherapy (nac) reasonable strategy among cn3 patients based results recent sr reported radiological response rates approximately 53% pathological complete response approximately 12.8% patients . review consisted mostly retrospective series; complete response rates intention treat population 10% (paclitaxel, ifosfamide, cisplatin [tip]) 4% (docetaxel, cisplatin fluorouracil [tpf]) prospective trials . responding patients, evidence disease progression, surgical resection remove residual disease utilizing radical inguinal plnd techniques preferred strategy. detailed examination peri-operative chemotherapy please see section 6.4.1. pre-operative radiotherapy used single study among cn3 cohort 12 patients reported objective response 2 patients 7 12 patients subsequently undergoing ilnd. 2 patients (17%) survived 5 years . worth recognising data, however, utilises historical radiotherapy techniques precluding meaningful extrapolation modern practice (see section 6.4.2 details). surgery initial treatment patients fixed inguinal mass clinically evident pelvic adenopathy (cn3) presentation recurrence discouraged routine management. often technically feasible “surgery first approach” often results large skin/soft tissue defects, need myocutaneous flap reconstruction, prolonged hospital stays (mean median 8.5–23 days) associated high overall complication rates (65–77%) . single-centre study among 24 patients treated surgical debulking alone advanced disease setting, median css dfs six three months, respectively . study 17.5% patients exhibited rapid progression disease post-surgery never received adjuvant therapy . 6.3.3. patient selection consolidative radical inguinal/pelvic lymphadenectomy patients whose tumours respond nac subsequently undergo surgical consolidation represent favourable subgroup patients mean 5-year survival 56.9% according sr . among cn3 patients candidates conventional multi-agent chemotherapy, pre-operative chemo-radiation/radiation offered attempt downsize tumours improve resectability. evidence this, however, recognised weak prospectively investigated inpact study . 6.3.4. surgical technique 6.3.4.1. inguinal lymph node dissection surgical resection proceed 5–8 weeks completion chemotherapy provide time haematologic recovery therapy related symptoms improve. pre-operative planning remove residual disease taking consideration size mass, involvement surrounding structures, anticipated skin soft tissue defects well plastic surgical consultation (as appropriate) required successful outcomes. 6.3.4.2. lymphadenectomy boundaries surgical boundaries follow ‘radical inguinal lymph node’ dissection” (described table 6.1). wide resection involved skin often required en bloc ilnd. considering extent inguinal metastases along fixation adjacent structures, minimally-invasive techniques (i.e., robotic-, laparoscopic ilnd) considered inappropriate cn3 inguinal metastases. 6.3.4.3. pelvic lymph node dissection simultaneous plnd performed time ilnd pelvic ln metastases clinically evident diagnosis. ipsilateral plnd also performed simultaneous (preferred) delayed fashion setting advanced bulky inguinal metastases without clinically evident pelvic metastases well (i.e., prophylactic). latter setting, microscopic pelvic metastases noted quite frequently (44–100%) setting extracapsular disease especially inguinal mass present one series . 6.3.4.4. surgical complications cn3 disease resection bulky/fixed inguinal masses without prior chemotherapy associated variety complications. minor complications requiring hospitalization surgical intervention common tolerable cure significant palliation achieved. major post-surgical complications requiring medical surgical intervention associated disability, death, several series included infection/sepsis (1.5–4.5%), lymphocele requiring drainage (0–3.8%), wound dehiscence necrosis requiring debridement (1.5–5.6%), pneumonia (0–2.9%), deep venous thrombosis/pulmonary embolus (0–8.7% death (0–5.6%) . overall, three selected series patients treated experienced centres incidence major complications described less one ten patients 3/82 (3.9%) patients succumbing sepsis early peri-operative complications. 6.3.5. summary evidence guidelines surgical management cn3 disease summary evidencelesurgery alone rarely cure patients cn3 disease.3even technically feasible, upfront surgery associated significant complications may delay prevent delivery adjuvant therapy.3about half patients advanced (cn2–cn3) penile cancer respond combination chemotherapy. responders subsequently undergo consolidative inguinal/plnd os chance 50% 5 years.2ainguinal lnd cn3 patients often requires resection overlying skin effectively remove fixed bulky nodal mass.4the available literature includes virtually cn3 patients assess efficacy safety minimally-invasive ilnd.4 recommendationsstrength ratingoffer neoadjuvant chemotherapy (nac) using cisplatin- taxane-based combination chemotherapy-fit patients pelvic lymph node involvement extensive inguinal involvement (cn3), preference front surgery. (see section 6.4.1).weakoffer surgery patients responding nac resection feasible.strongoffer surgery patients progressed nac, resection feasible. see also (chemo)radiation.weakdo offer video endoscopic inguinal lymphadenectomy.strong